Brief: SCYNEXIS Resumes Patient Dosing In Phase 3 MARIO Study
28/05/2025 15:13
May 28 (Reuters) - SCYNEXIS Inc SCYX.O: SCYNEXIS RESUMES PATIENT DOSING IN PHASE 3 MARIO STUDY SCYNEXIS INC - RESUMPTION OF DOSING TRIGGERS $10M MILESTONE PAYMENT FROM GSK SCYNEXIS INC - WORKING TO RESOLVE DISAGREEMENT WITH GSK SCYNEXIS INC - GSK DISPUTES MILESTONE PAYMENTS, SCYNEXIS DISAGREES WITH GSK'S POSITION Source text: ID:nGNX9BwNBS Further company coverage: SCYX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Scynexis
See all newsBrief: Scynexis Announces Phase 1 Study Results For Scy-770, A Novel, Highly Selective, Oral Direct Ampk Activator For The Treatment Of Autosomal Dominant Polycystic Kidney Disease
Brief: Scynexis Announces Appointment Of Sanjay Subramanian As Chief Financial Officer
Scynexis Inc Reports Results For The Quarter Ended June 30: Earnings Summary
Scynexis Q2 swings to profit on warrant adjustment; advances drug studies
Scynexis Inc Expected To Post A Loss Of 51 Cents A Share: Earnings Preview